MarkKirschbaumMD

Hematology • Hershey, PA

Hematologic Oncology

CMO & SVP, Cyclacel Pharmaceuticals, NJ

Join to view full profile

Dr. Kirschbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kirschbaum's full profile

Already have an account?

Office
500 University Dr
Hershey, PA 17033
Phone+1 800-243-1455

Education & Training

SUNY Downstate Health Sciences UniversityInternship, Internal Medicine, 1986 - 1987
State University of New York Downstate Medical Center College of MedicineClass of 1986

Certifications & Licensure

NY State Medical License 1988 - 2026
PA State Medical License 2012 - 2016
NV State Medical License Active through 2013
CA State Medical License 2002 - 2012
American Board of Internal Medicine Internal Medicine

Clinical Trials

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2004 Oct 01
Completed
Phase 1
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1
Aflibercept in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2007 Sep 01
Terminated
Phase 2
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab Start of enrollment: 2010 May 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1705 citations
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment o...
Shimon Slavin, Arnon Nagler, Ella Naparstek, Yossi Kapelushnik, Memet Aker
Blood. 1998-02-01
242 citations
Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Michael Andreeff, Kevin R. Kelly, Karen W.L. Yee, Sarit Assouline, Roger Strair
Clinical Cancer Research. 2016-02-15
206 citations
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes, Anna Sureda, Dina Ben-Yehuda, Pier Luigi Zinzani, Tee Chuan Ong
Journal of Clinical Oncology. 2012-04-30

Press Mentions

Cyclacel Reports Preliminary Data from Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022October 26th, 2022
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 10th, 2022
BioSpace Movers & Shakers, Oct. 30October 29th, 2020
Join now to see all